Protocol I8K-MC-JPDA-A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of LY3337641 in Adult Subjects With Moderate to Severe Rheumatoid Arthritis: The RAjuvenate Study
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2017
At a glance
- Drugs Poseltinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RAjuvenate
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 06 Jan 2017 Planned number of patients changed from 182 to 276.
- 06 Jan 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2019.